Sil Amrita, Das Nilay Kanti
Department of Pharmacology, Institute of Post Graduate Medical Education and Research, Kolkata, West Bengal, India.
Department of Dermatology, Medical College, Kolkata, West Bengal, India.
Indian J Pharmacol. 2014 May-Jun;46(3):334-6. doi: 10.4103/0253-7613.132189.
Sorafenib, a multikinase inhibitor, is approved for treatment of renal cell cancer and hepatocellular cancer. Hand-foot syndrome (HFD) is a condition where erythema, scaling, and bullous lesion affect the hand and feet. In this case, a post-nephrectomy renal carcinoma patient prescribed sorafenib developed HFD 1 week after the drug usage. All laboratory parameters were within normal limits. The dose of sorafenib was reduced and topical corticosteroids, antihistamines, and emollients were prescribed. The reaction reduced after 2 weeks of therapy, only to reappear again when the second cycle of sorafenib-targeted therapy was started. The case was diagnosed as sorafenib-induced HFD.
索拉非尼是一种多激酶抑制剂，已被批准用于治疗肾细胞癌和肝细胞癌。手足综合征（HFS）是一种红斑、脱屑和水疱性病变累及手足的病症。在此病例中，一名接受肾切除术后的肾癌患者在服用索拉非尼1周后出现了手足综合征。所有实验室参数均在正常范围内。索拉非尼剂量减少，并开具了外用皮质类固醇、抗组胺药和润肤剂。治疗2周后反应减轻，但在开始索拉非尼靶向治疗的第二个周期时再次出现。该病例被诊断为索拉非尼诱导的手足综合征。
